These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18391047)

  • 1. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
    Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM;
    Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
    Baines SD; Freeman J; Wilcox MH
    Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
    Hussack G; Tanha J
    Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
    Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
    Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human peptide α-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT.
    Fischer S; Ückert AK; Landenberger M; Papatheodorou P; Hoffmann-Richter C; Mittler AK; Ziener U; Hägele M; Schwan C; Müller M; Kleger A; Benz R; Popoff MR; Aktories K; Barth H
    FASEB J; 2020 May; 34(5):6244-6261. PubMed ID: 32190927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.
    Weiss K
    Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.
    Sambol SP; Merrigan MM; Lyerly D; Gerding DN; Johnson S
    Infect Immun; 2000 Oct; 68(10):5480-7. PubMed ID: 10992443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
    Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
    Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
    Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
    Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.
    Guilbault C; Labbé AC; Poirier L; Busque L; Béliveau C; Laverdière M
    J Clin Microbiol; 2002 Jun; 40(6):2288-90. PubMed ID: 12037113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
    Scheinfeld N; Biggers K
    Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
    Steele J; Parry N; Tzipori S
    Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Importance of Therapeutically Targeting the Binary Toxin from
    Abeyawardhane DL; Godoy-Ruiz R; Adipietro KA; Varney KM; Rustandi RR; Pozharski E; Weber DJ
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.